Pivoting To RNA With Circio's Dr. Erik Digman Wiklund

Business Of Biotech

We love to hear from our listeners. Send us a message.

This week, it’s another “Business of Biotech-meets-Business-of-RNA” takeover with Circio CEO Erik Digman Wiklund, Ph.D. and guest co-host Anna Rose Welch of Advancing RNA. While Circio’s legacy is in cancer immunology (it still boasts a cancer vaccine candidate targeting KRAS driver mutations), the company made a bold pivot, of sorts, when it committed headlong to the circular RNA future. Now, it’s in the throes of fine-tuning a platform for the development of novel circRNA medicines for rare disease, vaccines, and cancer. On this episode of the Business of Biotech, we go deep inside the story behind the pivot, we explore the RNA therapeutic platform-versus-product appetite among biotech investors, and Dr. Digman Wiklund shares insights into the challenges his company overcame to enable such a dramatic shift in focus.

Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com.

Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: [e-mail]
Find Matt Pillar on LinkedIn: https://www.linkedin.com/in/matthewpillar/

Capitoli

1. Pivoting To RNA With Circio's Dr. Erik Digman Wiklund (00:00:00)

2. The Art of Business Pivots (00:00:04)

3. Exploring Circular RNA in Gene Therapy (00:14:05)

4. Advancing Circular RNA in Gene Therapy (00:22:13)

5. Transitioning to Gene Therapy Development (00:33:29)

6. Navigating the Circular RNA Industry (00:41:39)

7. Future of Gene Therapy Innovations (00:52:10)

8. Life Science Connect Podcast Recap (01:03:57)